Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022
Wendy Carr, Ekaterina V. Kurbatova, Angela M. Starks, Neela D. Goswami, Leeanna Allen, Carla A. Winston
Abstract
On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine (RPT), moxifloxacin (MOX), isoniazid (INH), and pyrazinamide (PZA) was as effective as the standard 6-month regimen for tuberculosis (TB) treatment (1). On the basis of these findings, CDC recommends the 4-month regimen as a treatment option for U.S. patients aged ≥12 years with drug-susceptible pulmonary TB and provides implementation considerations for this treatment regimen.
Topics & Concepts
RifapentineMedicineMoxifloxacinRegimenPyrazinamideIsoniazidTuberculosisInterimClinical trialInterim analysisInternal medicineRandomized controlled trialMycobacterium tuberculosisAntibioticsLatent tuberculosisPathologyMicrobiologyHistoryArchaeologyBiologyTuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisMycobacterium research and diagnosis